期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 83, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.intimp.2020.106388
关键词
Low-dose naltrexone (LDN); Opioid growth factor receptor (OGFr); Colorectal cancer (CRC) progression; Apoptosis; M1-like macrophages; Bax/Bcl-2/caspase-3/PARP
资金
- National Natural Science Foundation of China [31670921]
- Natural Science Foundation of Liaoning Province, China [2019-ZD-0747]
The incidence of colorectal cancer (CRC) is increasing annually worldwide. However, traditional chemotherapy has obvious side effects. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Therefore, the aim of this study was to explore the mechanisms underlying the inhibitory effect of LDN on CRC progression in vivo and in vitro. We found that expression of macrophage markers (F4/80, CD68) was increased in nude mice treated with LDN compared with the control group (p < 0.05). Additionally, levels of M1 macrophage phenotypic markers (CD80) and cytokines (tumor necrosis factor-alpha, TNF-alpha) were higher than in the control group (p < 0.05). LDN was able to upregulate expression of the opioid growth factor receptor (OGFr) and apoptosis-related factors Bax, caspase-9, caspase-3, and PARP and downregulate expression of Bcl-2, Survivin, and Ki67 to promote tumor cell apoptosis. Therefore, we speculate that LDN reduces tumor size by increasing levels of M1-like macrophages and activating the Bax/Bcl-2/caspase-3/PARP signaling pathway to induce apoptosis. We suggest that LDN has potential for the treatment of CRC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据